ABS-201 in Androgenetic Alopecia

Trial
100%50%0%Jun 25Jun 26Jun 27Jun 28Jun 29Jun 30Jul 1Jul 2Jul 3Jul 4Jul 5Jul 6Jul 7Jul 8Jul 9Jul 10Jul 11Jul 12Jul 13Jul 14Jul 15Jul 16Jul 17Jun 25 • YES 31.9%Jun 29 • YES 32.9%Jun 30 • YES 32.9%Jul 1 • YES 100.0%Jul 2 • YES 48.4%Jul 3 • YES 93.5%Jul 4 • YES 93.5%Jul 5 • YES 93.5%Jul 6 • YES 94.4%Jul 7 • YES 2.7%Jul 8 • YES 99.8%Jul 9 • YES 6.8%Jul 10 • YES 100.0%Jul 17 • YES 99.9%
Stock ($ABSI)Daily close · through Jul 17
No stock close$11.99$9.85$7.71Jun 25Jun 26Jun 27Jun 28Jun 29Jun 30Jul 1Jul 2Jul 3Jul 4Jul 5Jul 6Jul 7Jul 8Jul 9Jul 10Jul 11Jul 12Jul 13Jul 14Jul 15Jul 16Jul 17Jul 9 • ABSI $11.47Jul 10 • ABSI $10.60Jul 13 • ABSI $10.21Jul 14 • ABSI $10.23Jul 15 • ABSI $9.76Jul 16 • ABSI $8.23Jul 17 • ABSI $8.30

Will Absci report a numerical improvement in Target Area Hair Count (TAHC) for ABS-201 in AGA patients by Dec. 31, 2026?

Create account to trade

Matched news3 items

All news
ABSI

Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)

Study medication appears well tolerated, with favorable safety data across all blinded single ascending dose (SAD) cohorts Estimated half-life of at least 65 days supports potential for ABS-201 targeted dosing interval of two or three injections over six-month period First multiple ascending dose

Interim Data • Phase 1Interim data Mon, Jun 8, 2026Exact NCT match: NCT07317544
ABSI

Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results

Successfully dosed all four planned healthy volunteer SAD cohorts of ongoing ABS-201™ HEADLINE trial; well-tolerated with favorable emerging safety data Preliminary pharmacokinetic (PK) modeling from HEADLINE trial supports ABS-201's targeted dosing interval Initiated dosing of first MAD cohort of

Interim Data • Phase 1Matched abs-201, androgenetic, alopecia, anti-prlr, antibody
ABSI

Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results

Successfully dosed first three cohorts in SAD portion of ongoing ABS-201™ HEADLINE trial; well-tolerated with favorable emerging safety data Unveiled human ex vivo data demonstrating that ABS-201 stimulates hair growth and regenerates follicle stem cell niche Appointed seasoned biopharmaceutical

Interim Data • Phase 1Matched abs-201, androgenetic, alopecia, anti-prlr, antibody